Sugi Predict

Sugi Predict / Compounds / SCHEMBL2637460

SCHEMBL2637460

SCHEMBL2637460

Cc1cc(C(F)(F)F)cc(S(=O)(=O)N2CCC3(CCNC3=O)CC2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 1/20 0.47
▸ JAK2 O60674 1/20 0.41
▸ JAK1 P23458 1/20 0.41
▸ TYK2 P29597 1/20 0.41
▸ JAK3 P52333 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ GAA P10253 2/20 0.39
▸ LMNA P02545 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ SLC34A1 Q06495 1/20 0.38
▸ CNR1 P21554 2/20 0.38
▸ CYP2D6 P10635 2/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CCNC P24863 1/20 0.36
▸ CDK8 P49336 1/20 0.36
▸ OTUD7B Q6GQQ9 1/20 0.35
▸ HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2637373 0.92 IDO1 (0.49) IDO1JAK2JAK1TYK2JAK3
SCHEMBL2637213 0.87 IDO1 (0.46) IDO1JAK2JAK1TYK2JAK3
SCHEMBL2635300 0.87 IDO1 (0.40) IDO1JAK2JAK1TYK2JAK3
SCHEMBL2638708 0.86 IDO1 (0.45) IDO1JAK2JAK1TYK2JAK3
SCHEMBL2637275 0.86 CNR1 (0.47) IDO1JAK2JAK1TYK2JAK3
SCHEMBL2637598 0.83 HTT (0.54) IDO1GAALMNACNR1SMN1; SMN2
SCHEMBL2637421 0.82 ALDH1A1 (0.50) IDO1JAK2JAK1TYK2JAK3
SCHEMBL2637173 0.81 IDO1 (0.40) IDO1ALDH1A1L3MBTL1GAACNR1
SCHEMBL2637353 0.81 JAK1 (0.48) IDO1JAK2JAK1TYK2JAK3
SCHEMBL2637266 0.80 JAK1 (0.47) IDO1JAK2JAK1TYK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130116270-A1 NOVEL COMPOUNDS CONVERGENCE PHARMACEUTICALS LIMTED 2013-05-09 — — US claimed
EP-2569318-A1 NOVEL COMPOUNDS Convergence Pharmaceuticals Limited (GB) 2013-03-20 — — EP claimed
WO-2011141729-A1 NOVEL COMPOUNDS Convergence Pharmaceuticals Limited (GB) 2011-11-17 — — WO claimed
US-20130116270-A1 NOVEL COMPOUNDS CONVERGENCE PHARMACEUTICALS LIMTED 2013-05-09 — — US disclosed
US-20130116270-A1 NOVEL COMPOUNDS CONVERGENCE PHARMACEUTICALS LIMTED 2013-05-09 — — US disclosed
US-20130116270-A1 NOVEL COMPOUNDS CONVERGENCE PHARMACEUTICALS LIMTED 2013-05-09 — — US disclosed
EP-2569318-A1 NOVEL COMPOUNDS Convergence Pharmaceuticals Limited (GB) 2013-03-20 — — EP disclosed
WO-2011141729-A1 NOVEL COMPOUNDS Convergence Pharmaceuticals Limited (GB) 2011-11-17 — — WO disclosed
WO-2011141729-A1 NOVEL COMPOUNDS Convergence Pharmaceuticals Limited (GB) 2011-11-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116270-A1 NOVEL COMPOUNDS TRPV2, CACNA1C, CACNA1B IDO1 4772/4885JAK2 3896/4885JAK1 4820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.